By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German molecular diagnostics firm Epigenomics today reported that its first-half revenues increased 1 percent year over year, and the firm is implementing a restructuring that will include cutting its staff by nearly half.

The Berlin-based firm reported first-half revenues of €990,000 ($1.4 million), compared to €970,000 for the first half of 2010. Its net loss increased 10 percent to €5.90 from €5.40.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.